Stage (next event)
Catalyst Info & Data Links
TITLE: IFX-1 (vilobelimab) in Hidradenitis Suppurativa (HS)
ClinicalTrials.gov (NCT03487276): Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (SHINE)
ClinicalTrials.gov (NCT03001622): Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2018: Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?. British Journal of Dermatology, 179(2), 413-419.
Mechanism of Action
MECHANISM OF ACTION
IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis and Pyoderma Gangraenosum.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post